Nabil El Zein

Nabil El Zein

Auto-generated profile, based on publicly available information

Nabil El Zein

Hemato-Oncology Unit and Laboratory of Pediatric Oncology, Hôpital Universitaire des Enfants, Brussels, Belgium

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2009 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
RRRedouane Rouas
Redouane Rouas
HFHussein Fayyad‐Kazan
Hussein Fayyad‐Kazan
NZNabil El Zein
Nabil El Zein
PLPhilippe Lewalle
Philippe Lewalle
FRFrançoise Rothé
Françoise Rothé
BBBassam Badran
Bassam Badran
Treg are the main mediators of dominant tolerance. Their mechanisms of action and applications are subjects of considerable debate currently. However, a human microRNA (miR) Treg signature has not been described yet. We investigated human natural Treg and identified a signature composed of five miR (21, 31, 125a, 181c and 374). Among those, two were considerably under‐expressed (miR‐31 and miR‐125a). We identified a functional target sequence for miR‐31 in the 3′ untranslated region (3′ UTR) of FOXP3 mRNA. Using lentiviral transduction of fresh cord blood T cells, we demonstrated that miR‐31 and miR‐21 had an effect on FOXP3 expression levels. We showed that miR‐31 negatively regulates FOXP3 expression by binding directly to its potential target site in the 3′ UTR of FOXP3 mRNA. We next demonstrated that miR‐21 acted as a positive, though indirect, regulator of FOXP3 expression. Transduction of the remaining three miR had no direct effect on FOXP3 expression or on the phenotype and will remain the subject of future investigations. In conclusion, not only have we identified and validated a miR signature for human natural Treg, but also unveiled some of the mechanisms by which this signature was related to the control of FOXP3 expression in these cells.

1 March 2012 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
HFHussein Fayyad-Kazan
Hussein Fayyad-Kazan
RRRedouane Rouas
Redouane Rouas
MFMohammad Fayyad-Kazan
Mohammad Fayyad-Kazan
RBRabih Badran
Rabih Badran
NZNabil El Zein
Nabil El Zein
PMPhilippe Martiat
Philippe Martiat
Regulatory T cells (Tregs) are characterized by a high expression of IL-2 receptor α chain (CD25) and of forkhead box P3 (FOXP3), the latter being essential for their development and function. Another major player in the regulatory function is the cytotoxic T-lymphocyte associated molecule-4 (CTLA-4) that inhibits cytotoxic responses. However, the regulation of CTLA-4 expression remains less well explored. We therefore studied the microRNA signature of circulating CD4+ Tregs isolated from adult healthy donors and identified a signature composed of 15 differentially expressed microRNAs. Among those, miR-24, miR-145, and miR-210 were down-regulated in Tregs compared with controls and were found to have potential target sites in the 3′-UTR of FOXP3 and CTLA-4; miR-24 and miR-210 negatively regulated FOXP3 expression by directly binding to their two target sites in its 3′-UTR. On the other hand, miR-95, which is highly expressed in adult peripheral blood Tregs, positively regulated FOXP3 expression via an indirect mechanism yet to be identified. Finally, we showed that miR-145 negatively regulated CTLA-4 expression in human CD4+ adult peripheral blood Tregs by binding to its target site in CTLA-4 transcript 3′-UTR. To our knowledge, this is the first identification of a human adult peripheral blood CD4+ Treg microRNA signature. Moreover, unveiling one mechanism regulating CTLA-4 expression is novel and may lead to a better understanding of the regulation of this crucial gene.

28 July 2015 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KZKazem Zibara
Kazem Zibara
ZAZahraa Awada
Zahraa Awada
LDLeila Dib
Leila Dib
JEJamal El-Saghir
Jamal El-Saghir
SASara Al-Ghadban
Sara Al-Ghadban
MEMarwan El-Sabban
Marwan El-Sabban
Cancer cells secrete VEGF, which plays a key role in their growth, invasion, extravasation and metastasis. Direct cancer cell-endothelial cell interaction, mediated by gap junctions, is of critical importance in the extravasation process. In this study, we evaluated avastin (Av), an anti-VEGF antibody; and oleamide (OL), a gap junction inhibitor, using MDA-MB-231 human breast cancer cells in vitro and a xenograft murine model in vivo. Results showed that Av/OL significantly decreased proliferation, induced cell cycle arrest and decreased migration and invasion of MDA-MB-231 cells in vitro. In addition, Av/OL significantly decreased homo and hetero-cellular communication interaction between MDA-MDA and MDA-endothelial cells, respectively. The expression levels of several factors including VEGF, HIF1α, CXCR4, Cx26, Cx43 and MMP9 were attenuated upon Av/OL treatment in vitro. On the other hand, avastin, but not oleamide, reduced tumor size of NSG mice injected subdermally (s.d.) with MDA-MB-231 cells, which was also associated with increased survival. Furthermore, Av but also OL, separately, significantly increased the survival rate and reduced pulmonary and hepatic metastatic foci, of intravenously (i.v.) injected mice. Finally, OL reduced MMP9 protein expression levels, better than Av and in comparisons to control, in the lungs of MDA-MB-231 i.v. injected NSG mice. In conclusion, while avastin has anti-angiogenic, anti-tumor and anti-metastatic activities, oleamide has anti-metastatic activity, presumably at the extravasation level, providing further evidence for the role of gap junction intercellular communication (GJIC) in cancer cell extravasation.

1 July 2014 in Human Immunology
Verified
Journal Article
Closed access
HFHussein Fayyad-Kazan
Hussein Fayyad-Kazan
EHEva Hamade
Eva Hamade
RRRedouane Rouas
Redouane Rouas
MNMehdi Najar
Mehdi Najar
MFMohammad Fayyad-Kazan
Mohammad Fayyad-Kazan
BBBassam Badran
Bassam Badran

7 April 2016 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
WNWared Nour-Eldine
Wared Nour-Eldine
CGCrystal M. Ghantous
Crystal M. Ghantous
KZKazem Zibara
Kazem Zibara
LDLeila Dib
Leila Dib
HIHawraa Issa
Hawraa Issa
AZAsad Zeidan
Asad Zeidan
INTRODUCTION: Adiponectin (APN), an adipocytokine, exerts protective effects on cardiac remodeling, while angiotensin II (Ang II) induces hypertension and vascular remodeling. The potential protective role of APN on the vasculature during hypertension has not been fully elucidated yet. Here, we evaluate the molecular mechanisms of the protective role of APN in the physiological response of the vascular wall to Ang II. METHODS AND RESULTS: Rat aortic tissues were used to investigate the effect of APN on Ang II-induced vascular remodeling and hypertrophy. We investigated whether nitric oxide (NO), the RhoA/ROCK pathway, actin cytoskeleton remodeling, and reactive oxygen species (ROS) mediate the anti-hypertrophic effect of APN. Ang II-induced protein synthesis was attenuated by pre-treatment with APN, NO donor (SNAP), or cGMP. The hypertrophic response to Ang II was associated with a significant increase in RhoA activation and vascular force production, which were prevented by APN and SNAP. NO was also associated with inhibition of Ang II-induced phosphorylation of cofilin. In addition, immunohistochemistry revealed that 24 hr Ang II treatment increased the F- to G-actin ratio, an effect that was inhibited by SNAP. Ang II-induced ROS formation and upregulation of p22phox mRNA expression were inhibited by APN and NO. Both compounds failed to inhibit Nox1 and p47phox expression. CONCLUSIONS: Our results suggest that the anti-hypertrophic effects of APN are due, in part, to NO-dependent inhibition of the RhoA/ROCK pathway and ROS formation.

1 October 2010 in Cellular Signalling
Verified
Journal Article
Closed access
NZNabil El Zein
Nabil El Zein
SDStéphanie D'Hondt
Stéphanie D'Hondt
ESEric Sariban
Eric Sariban